Sfoglia per Autore
Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
2019 Cesini, Laura; Carmosino, Ida; Breccia, Massimo; De Benedittis, Daniela; Mohamed, Sara; DE LUCA, MARIA LUCIA; Colafigli, Gioia; Molica, Matteo; Scalzulli, Emilia; Massaro, Fulvio; Mariggiò, Elena; Rizzo, Lorenzo; Loglisci, MARIA GIOVANNA; Scamuffa, MARIA CRISTINA; Vozella, Federico; Diverio, Daniela; Mancini, Marco; Alimena, Giuliana; Robin, Foà; Latagliata, Roberto
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice
2019 Scalzulli, Emilia; Molica, Matteo; Alunni Fegatelli, Danilo; Colafigli, Gioia; Rizzo, Lorenzo; Mancini, Marco; Efficace, Fabio; Latagliata, Roberto; Foà, Robin; Breccia, Massimo
Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome
2019 Colafigli, Gioia; Scalzulli, Emilia; Porrazzo, Marika; Diverio, Daniela; Loglisci, Maria Giovanna; Latagliata, Roberto; Guarini, Anna; Foa, Robin; Breccia, Massimo
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
2019 Molica, Matteo; Colafigli, Gioia; Scalzulli, Emilia; Fegatelli, Danilo Alunni; Ranieri, Sofia Chiatamone; Rizzo, Lorenzo; Diverio, Daniela; Efficace, Fabio; Latagliata, Roberto; Foa, Robin; Breccia, Massimo
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
2019 Molica, Matteo; Scalzulli, Emilia; Colafigli, Gioia; Foà, Robin; Breccia, Massimo
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
2019 Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R.
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
2019 Molica, Matteo; Scalzulli, Emilia; Colafigli, Gioia; Foà, Robin; Breccia, Massimo
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab
2020 Di Prima, A.; Botticelli, A.; Scalzulli, E.; Colafigli, G.; Pepe, S.; Lisi, C.; Marchetti, P.; Martelli, M.; Foa, R.; Breccia, M.
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance
2020 Mohamed, Sara; Latagliata, Roberto; Limongi, Maria Zaira; Nigro, Stefania; Sangiorgi, Eleonora; Nanni, Mauro; Piccioni, Annalina; Campagna, Alessia; Spiriti, Maria Antonietta Aloe; Carmosino, Ida; Molica, Matteo; Mariggio, Elena; Rosati, Serena; Colafigli, Gioia; Fazio, Francesca; De Luca, Maria Lucia; De Benedittis, Daniela; Scalzulli, Emilia; Breccia, Massimo; Mancini, Marco
The advantages and risks of ruxolitinib for the treatment of polycythemia vera
2020 Colafigli, G.; Scalzulli, E.; Pepe, S.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M.
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia. is it time to introduce it in the clinical practice?
2020 Colafigli, G.; Scalzulli, E.; Di Prima, A.; Pepe, S.; Loglisci, M. G.; Diverio, D.; Martelli, M.; Foa, R.; Breccia, M.
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
2020 Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.
The advantages and risks of ruxolitinib for the treatment of polycythemia vera
2020 Colafigli, Gioia; Scalzulli, Emilia; Pepe, Sara; DI PRIMA, Alessio; Efficace, Fabio; Martelli, Maurizio; Foa, Robin; Breccia, Massimo
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients
2020 Scalzulli, E.; Colafigli, G.; Latagliata, R.; Pepe, S.; Diverio, D.; Stocchi, F.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M.
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
2020 Pepe, Sara; Scalzulli, Emilia; Colafigli, Gioia; DI PRIMA, Alessio; Diverio, Daniela; Mancini, Marco; Latagliata, Roberto; Martelli, Maurizio; Robin, Foà; Breccia, Massimo
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice
2020 Breccia, Massimo; Efficace, Fabio; Colafigli, Gioia; Scalzulli, Emilia; Di Prima, Alessio; Martelli, Maurizio; Foà, Robin
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
2021 Latagliata, Roberto; Carmosino, Ida; Di Veroli, Ambra; Scalzulli, Emilia; Colafigli, Gioia; Scamuffa, Maria Cristina; Di Prima, Alessio; De Gregoris, Cinzia; Pepe, Sara; Mancini, Marco; Trape, Giulio; Martelli, Maurizio; Foa, Robin; Breccia, Massimo; Brecci, Massimo
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab
2021 DI PRIMA, Alessio; Botticelli, Andrea; Scalzulli, Emilia; Colafigli, Gioia; Pepe, Sara; Lisi, Chiara; Marchetti, Paolo; Martelli, Maurizio; Foà, Robin; Breccia, Massimo
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
2021 Scalzulli, Emilia; Caocci, Giovanni; Efficace, Fabio; Rizzo, Lorenzo; Colafigli, Gioia; Di Prima, Alessio; Pepe, Sara; Fegatelli, Danilo Alunni; Carmosino, Ida; Diverio, Daniela; Latagliata, Roberto; La Nasa, Giorgio; Martelli, Maurizio; Foa, Robin; Breccia, Massimo
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up
2021 Scalzulli, Emilia; Colafigli, Gioia; Pepe, Sara; DE LUCA, Giulia; DI PRIMA, Alessio; Efficace, Fabio; Diverio, Daniela; Latagliata, Roberto; Martelli, Maurizio; Robin, Foà; Breccia, Massimo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib | 2019 | Cesini, Laura; Carmosino, Ida; Breccia, Massimo; De Benedittis, Daniela; Mohamed, Sara; DE LUCA, MARIA LUCIA; Colafigli, Gioia; Molica, Matteo; Scalzulli, Emilia; Massaro, Fulvio; Mariggiò, Elena; Rizzo, Lorenzo; Loglisci, MARIA GIOVANNA; Scamuffa, MARIA CRISTINA; Vozella, Federico; Diverio, Daniela; Mancini, Marco; Alimena, Giuliana; Robin, Foà; Latagliata, Roberto | |
| Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice | 2019 | Scalzulli, Emilia; Molica, Matteo; Alunni Fegatelli, Danilo; Colafigli, Gioia; Rizzo, Lorenzo; Mancini, Marco; Efficace, Fabio; Latagliata, Roberto; Foà, Robin; Breccia, Massimo | |
| Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome | 2019 | Colafigli, Gioia; Scalzulli, Emilia; Porrazzo, Marika; Diverio, Daniela; Loglisci, Maria Giovanna; Latagliata, Roberto; Guarini, Anna; Foa, Robin; Breccia, Massimo | |
| Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life | 2019 | Molica, Matteo; Colafigli, Gioia; Scalzulli, Emilia; Fegatelli, Danilo Alunni; Ranieri, Sofia Chiatamone; Rizzo, Lorenzo; Diverio, Daniela; Efficace, Fabio; Latagliata, Roberto; Foa, Robin; Breccia, Massimo | |
| Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia | 2019 | Molica, Matteo; Scalzulli, Emilia; Colafigli, Gioia; Foà, Robin; Breccia, Massimo | |
| Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib | 2019 | Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R. | |
| Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia | 2019 | Molica, Matteo; Scalzulli, Emilia; Colafigli, Gioia; Foà, Robin; Breccia, Massimo | |
| Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab | 2020 | Di Prima, A.; Botticelli, A.; Scalzulli, E.; Colafigli, G.; Pepe, S.; Lisi, C.; Marchetti, P.; Martelli, M.; Foa, R.; Breccia, M. | |
| Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance | 2020 | Mohamed, Sara; Latagliata, Roberto; Limongi, Maria Zaira; Nigro, Stefania; Sangiorgi, Eleonora; Nanni, Mauro; Piccioni, Annalina; Campagna, Alessia; Spiriti, Maria Antonietta Aloe; Carmosino, Ida; Molica, Matteo; Mariggio, Elena; Rosati, Serena; Colafigli, Gioia; Fazio, Francesca; De Luca, Maria Lucia; De Benedittis, Daniela; Scalzulli, Emilia; Breccia, Massimo; Mancini, Marco | |
| The advantages and risks of ruxolitinib for the treatment of polycythemia vera | 2020 | Colafigli, G.; Scalzulli, E.; Pepe, S.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M. | |
| Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia. is it time to introduce it in the clinical practice? | 2020 | Colafigli, G.; Scalzulli, E.; Di Prima, A.; Pepe, S.; Loglisci, M. G.; Diverio, D.; Martelli, M.; Foa, R.; Breccia, M. | |
| Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience | 2020 | Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M. | |
| The advantages and risks of ruxolitinib for the treatment of polycythemia vera | 2020 | Colafigli, Gioia; Scalzulli, Emilia; Pepe, Sara; DI PRIMA, Alessio; Efficace, Fabio; Martelli, Maurizio; Foa, Robin; Breccia, Massimo | |
| Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients | 2020 | Scalzulli, E.; Colafigli, G.; Latagliata, R.; Pepe, S.; Diverio, D.; Stocchi, F.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M. | |
| Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience | 2020 | Pepe, Sara; Scalzulli, Emilia; Colafigli, Gioia; DI PRIMA, Alessio; Diverio, Daniela; Mancini, Marco; Latagliata, Roberto; Martelli, Maurizio; Robin, Foà; Breccia, Massimo | |
| Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice | 2020 | Breccia, Massimo; Efficace, Fabio; Colafigli, Gioia; Scalzulli, Emilia; Di Prima, Alessio; Martelli, Maurizio; Foà, Robin | |
| Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia | 2021 | Latagliata, Roberto; Carmosino, Ida; Di Veroli, Ambra; Scalzulli, Emilia; Colafigli, Gioia; Scamuffa, Maria Cristina; Di Prima, Alessio; De Gregoris, Cinzia; Pepe, Sara; Mancini, Marco; Trape, Giulio; Martelli, Maurizio; Foa, Robin; Breccia, Massimo; Brecci, Massimo | |
| Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab | 2021 | DI PRIMA, Alessio; Botticelli, Andrea; Scalzulli, Emilia; Colafigli, Gioia; Pepe, Sara; Lisi, Chiara; Marchetti, Paolo; Martelli, Maurizio; Foà, Robin; Breccia, Massimo | |
| Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients | 2021 | Scalzulli, Emilia; Caocci, Giovanni; Efficace, Fabio; Rizzo, Lorenzo; Colafigli, Gioia; Di Prima, Alessio; Pepe, Sara; Fegatelli, Danilo Alunni; Carmosino, Ida; Diverio, Daniela; Latagliata, Roberto; La Nasa, Giorgio; Martelli, Maurizio; Foa, Robin; Breccia, Massimo | |
| Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up | 2021 | Scalzulli, Emilia; Colafigli, Gioia; Pepe, Sara; DE LUCA, Giulia; DI PRIMA, Alessio; Efficace, Fabio; Diverio, Daniela; Latagliata, Roberto; Martelli, Maurizio; Robin, Foà; Breccia, Massimo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile